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It is well established that the incretin hormone glucagon-like peptide 1 (GLP-1) amplifies the insulin secretory response to glucose (1, 2) . Specifically, nutrient sensing in the gut promotes intestinal release of GLP-1, which, in turn, enhances insulin secretion by pancreatic β cells (3) (4) (5) . It is generally agreed that GLP-1 receptor (GLP-1R) signaling involves activation of adenylyl cyclase and increased cAMP generation, which, in turn, leads to cAMP-dependent activation of the PKA and exchange protein directly activated by cAMP (EPAC) pathways that promote insulin secretion in a glucose-dependent manner (1, 6) . However, bioactive GLP-1 has a very short half-life in plasma due to rapid degradation by dipeptidyl peptidase 4 (DPP-4), and thus postprandial plasma levels remain in the picomolar range (7, 8) . Even following therapeutic administration of a DPP-4 inhibitor, the circulating concentration of GLP-1 is only increased 2-fold (9) . This modest increase in circulating GLP-1 contrasts greatly with the majority of in vitro studies of GLP-1 action on the pancreatic islet, including our own (11, 12) , which relies on nanomolar concentrations of GLP-1 (or the DPP-4-resistant analog exendin-4).
This discrepancy between the concentration of circulating GLP-1 and the concentrations that have been used to stimulate insulin secretion in vitro raises questions about how GLP-1-dependent actions promote insulin release by pancreatic β cells. The reported observations of direct GLP-1 actions on islet function may not be physiologically relevant, and alternative hypotheses have been advanced that suggest that the actions of GLP-1 involve a neuronal gut-to-brain-toperiphery axis. Proponents of these pathways argue that L-cell-secreted GLP-1 influences brain neuronal activities via the vagus nerve, and the brain, in turn, transmits signals to the pancreas to regulate glucose homeostasis (12, 13) . While accumulating evidence supports the contribution of extrapancreatic GLP-1Rs, other studies continue to strengthen the notion that GLP-1R activation directly in the pancreas is sufficient for incretin control of insulin release (14) . However, the question remains as to how physiological concentrations of GLP-1 act on β cells to promote insulin secretion and whether this mechanism has any overlap with the "classical" mechanism(s) defined by studies using supraphysiological GLP-1.
A direct effect
In this issue, Shigeto and colleagues (15) analyzed human and murine pancreatic islets and show that picomolar concentrations of GLP-1 do indeed augment insulin secretion through direct interaction with the islet GLP-1R. Consistent with previous studies (16, 17) , Shigeto et al. confirm that GLP-1 action in pancreatic β cells is PKA dependent, as pharmacological PKA inhibitors reduced the insulinotropic effect. This block was only partial, suggesting a substantial PKA-independent contribution to the amplification of insulin secretion by GLP-1. Previous work has suggested that GLP-1R signaling is coupled to the activation of PLC (18) The ability of glucose to stimulate insulin secretion from the pancreatic islets of Langerhans is enhanced by the intestinal hormone glucagon-like peptide 1 (GLP-1), which is secreted from the gut in response to nutrient ingestion. This action, called the incretin effect, accounts for as much as half of the postprandial insulin response and is exploited therapeutically for diabetes treatment through the use of incretin mimetic drugs and inhibitors of dipeptidyl peptidase 4, which degrades GLP-1. Despite a prominent role for incretin mimetics in diabetes treatment, several key questions remain about GLP-1-induced insulin secretion. Most studies have examined the effects of GLP-1 at concentrations several orders of magnitude higher than those found in vivo; therefore, one might question the physiological (and perhaps even pharmacological) relevance of pathways identified in these studies and whether other important mechanisms might have been obscured. In this issue of the JCI, Shigeto and colleagues demonstrate that physiological GLP-1 does indeed amplify the insulin secretory response. Intriguingly, while much of this response is PKA dependent, as might be expected, the use of picomolar GLP-1 reveals a new and important mechanism that contributes to GLP-1-induced insulin secretion. The Journal of Clinical Investigation C o m m e n t a r y 4 suggest that cAMP may not rise sufficiently with picomolar amounts of GLP-1 to promote EPAC2A activation, a role for multiple EPAC2A targets cannot be ruled out. Likewise, further work will be required to determine whether the PKA-dependent component is activated (perhaps locally) by picomolar GLP-1 or is permissive for insulin secretion under this condition. AC, adenylyl cyclase; DAG, diacylglycerol; GK, glucokinase; GLUT, glucose transporter; VDCC, voltage-dependent Ca 2+ channels. cate that GLP-1 enhances glucose-stimulated insulin secretion by (a) recruiting an increased proportion of β cells to respond to glucose through increased excitability mediated by GLP-1 effects on metabolism and ion channels -effects that are both PKA-dependent and -independent (23) -and (b) promoting responsive β cells to secrete more insulin on a cell-by-cell basis through increased access of secretory granules to the plasma membrane (11) and the PKA-dependent phosphorylation of exocytotic proteins (25, 26) , leading to increased exocytotic responses. Importantly, Shigeto and colleagues provide evidence to support a direct insulinotropic effect of physiologically relevant concentrations of the GLP-1 hormone on the β cell. Their use of picomolar concentrations of GLP-1 to evoke membrane depolarization and increase insulin secretion reveals a heretofore unappreciated role for the Gα q -dependent activation of PLC, PKC, and TRPM4 and TRPM5 channels, which likely play an important role in the GLP-1-dependent recruitment of glucose-responsive β cells.
that include the PLC-dependent activation of TRPM4 and TRPM5 identified by Shigeto et al.) and enhances the secretory capacity of each β cell in a PKA-dependent manner downstream of electrical excitability and Ca 2+ entry (Figure 1 ).
Conclusions and future directions
The fact that Shigeto et al. (15) observed little or no cAMP and PKA activation directly in response to picomolar amounts of GLP-1 is somewhat perplexing. There are two possible scenarios to explain this apparent lack of cAMP/PKA activation: (a) localized cAMP/PKA signals were missed or obscured in the context of whole-cell measurements or, (b) at picomolar GLP-1 concentrations, PKA is not stimulated per se but instead plays a permissive role. These scenarios can also be applied to EPAC2A, which has long been implicated in GLP-1-induced insulin secretion. While Shigeto and colleagues suggest that the low levels of cAMP likely to be induced by picomolar concentrations of GLP-1 preclude involvement of EPAC in insulin secretion under this condition, this possibility remains uninvestigated and cannot be ruled out. Clearly, further investigation of the classical cAMP/PKA/EPAC pathways is required, and future studies should examine direct coupling to potential targets or use new and improved tools to measure cAMP/PKA/EPAC activity in β cells in response to physiological levels of GLP-1. For example, a more effective PKA antagonist with enhanced membrane permeability (Rp-8-pCPT-cAMPS-pAB) has recently been described (27) and used to demonstrate a role for PKA activity, in the absence of exogenous cAMP-raising agents, in biphasic glucose-stimulated insulin secretion (27) . Application of this tool should also provide additional insight into the relative contribution of cAMP-dependent and -independent effects of GLP-1R signaling. Additionally, it would be interesting to examine the effect of Rp-8-pCPT-cAMPSpAB on the insulinotropic response to picomolar GLP-1 concentrations. Taken together, the evidence from Shigeto et al. (15) contributes fresh information that provides added insight into the still-emerging network of insulinotropic actions and targets of GLP-1 in the β cell (Figure 1) . Collectively, these studies indi-
GLP-1 and critical to the advent of incretin mimetics and DPP-4 inhibitors for diabetes therapy. A mechanism whereby picomolar concentrations of GLP-1 alone are sufficient to promote β cell depolarization and action potential firing seems poorly aligned with the glucose dependence of GLP-1 action, as action potential firing should stimulate, rather than amplify, a secretory response. Critically, the experiments performed by Shigeto et al. (15) were largely performed with a concentration of glucose (6 mM) that is near the threshold for stimulating insulin secretion ( Figure  1A) ; therefore, the addition of picomolar concentrations GLP-1, which activated depolarizing TRPM4 and TRPM5 channels and inhibits hyperpolarizing K ATP channels (e.g., ref. 21), can effectively "sensitize" β cells and increase activity at threshold glucose concentrations. These effects, combined with activation of glucokinase (22) While activation of TRPM4 and TRPM5 channels can increase the proportion of β cells that respond to a glucose stimulus, this mechanism alone cannot make β cells secrete more insulin on a cell-by-cell basis. One or more additional mechanism(s) must work to augment the secretory response ( Figure 1C ). While elucidating a role for PLC-dependent regulation of TRPM4 and TRPM5 channels in GLP-1-mediated effects on insulin secretion, Shigeto et al. confirmed that PKA signaling and direct facilitation of the β cell exocytotic response are important for amplifying the insulin secretory response at physiological GLP-1 concentrations (15) . Based on these and other recent mechanistic insights, it seems likely that PKA directly augments insulin granule priming and responsiveness to Ca 2+ (25, 26) . Together, these studies indicate that GLP-1 increases the number of β cells that respond to glucose (through mechanisms
